Search results for " Clinical Trials"

showing 10 items of 79 documents

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

2020

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA an…

:Chemicals and Drugs::Pharmaceutical Preparations::Placebos [Medical Subject Headings]Physiologyα -lipoic acid ; thioctic acid ; dietary supplement ; safety ; meta-analysisClinical BiochemistryDisease030204 cardiovascular system & hematologyBiochemistrymeta-analysi:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings]Dietary supplementchemistry.chemical_compound0302 clinical medicinethioctic aciddietary supplement meta-analysis safety thioctic acid α-lipoic acid:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]α-lipoic acidLipoic acidSafety profile:Publication Type::Study Characteristics::Meta-Analysis [Medical Subject Headings]Suplementos dietéticosMeta-analysis:Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements [Medical Subject Headings]SafetysafetyAlpha-lipoic acidmedicine.medical_specialtyMEDLINEÁcido tióctico030209 endocrinology & metabolismPlacebo:Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiophenes::Thioctic Acid [Medical Subject Headings]Article:Health Care::Environment and Public Health::Public Health::Accidents::Accident Prevention::Safety [Medical Subject Headings]03 medical and health sciencesα‐lipoic acidThioctic acidInternal medicineDiabetes mellitusmedicineMetaanálisisAdverse effectSeguridad:Diseases::Cardiovascular Diseases [Medical Subject Headings]Molecular Biology:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Volatile [Medical Subject Headings]business.industryRevisión sistemáticalcsh:RM1-950Cell Biologymedicine.disease:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Food Habits::Smoking [Medical Subject Headings]meta-analysisMeta-analysislcsh:Therapeutics. Pharmacologychemistry:Diseases::Nervous System Diseases [Medical Subject Headings]dietary supplementMeta‐analysisbusinessAntioxidants
researchProduct

[Herpes Zoster and its prevention in Italy. Scientific consensus statement].

2014

In this paper, an Italian group of experts presents a revision of the available data about epidemiology and prevention of Herpes Zoster (HZ). HZ is an acute viral diseases caused by the reactivation of Varicella Zoster Virus (VZV). HZ is characterized by neurological and dermatological symptoms with a dermatomeric localization. The reactivation of the virus from the latent status in the sensitive ganglia increases with age and failing cell mediated immunity. In Europe, more than 95% of adults presents antibodies against VZV. Incidence of HZ is similar all over the world, related to the age of the population: from 2-3/1000 persons/year in the age group 20 to 50 years to 5/1000 in the 60 year…

AdultAged 80 and overClinical Trials as TopicEvidence-Based MedicineSettore MED/17 - Malattie InfettiveIncidenceSocio-culturaleNeuralgia Postherpeticconsensus statementMiddle AgedSettore MED/42 - Igiene Generale E ApplicataHerpes ZosterAge DistributionItalyRisk Factors80 and overNeuralgiaHerpes Zoster VaccineHumansAdult; Age Distribution; Aged; Aged 80 and over; Clinical Trials as Topic; Evidence-Based Medicine; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Italy; Middle Aged; Neuralgia Postherpetic; Risk Factors; SicilyPostherpeticSicilyprevention of herpes zosterAgedIgiene e sanita pubblica
researchProduct

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

2013

<b><i>Background and Objective:</i></b> We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). <b><i>Methods:</i></b> Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV<sub>1</sub>) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and …

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPulmonary diseaseComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionCohort StudiesPulmonary Disease Chronic ObstructiveRandomized controlled triallawForced Expiratory VolumeInternal medicinePragmatic Clinical Trials as TopicmedicineHumansCOPDAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overCOPDbusiness.industryPatient SelectionSmokingAge FactorsOxygen Inhalation TherapyRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityBronchiectasisrespiratory tract diseasesPhysical therapyFemaleObservational studyCognition DisordersbusinessCohort study
researchProduct

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy

2021

Therapies - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le mardi 13 avril 2021

AdultMale2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 vaccines030226 pharmacology & pharmacyArticle03 medical and health sciencesPharmacovigilance0302 clinical medicineBell's palsyPhase 3 clinical trialsBell PalsymedicineType I interferonsHumansBell's palsyPharmacology (medical)Potential mechanismComputingMilieux_MISCELLANEOUSAgedCOVID-19 coronavirus disease 2019Vaccines SyntheticMessenger RNASARS-CoV-2business.industryCOVID-19Bell’s palsyMiddle Agedmedicine.diseaseVirologymRNA messenger RNA3. Good healthInterferon Type IFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Interferon as treatment for acute hepatitis C

1996

The efficacy of short-course (three months), low-dose (3 million units three times a week) interferon as treatment for acute hepatitis C was evaluated in a meta-analysis of controlled trials. Nine studies (five randomized and four nonrandomized) found by MEDLINE search were eligible for analysis. The outcomes assessed were the rate of patients with normal serum aminotransferases (all trials) and without HCV RNA in blood (five trials) after posttreatment follow-up. Eight trials compared interferon to no treatment, and one compared different schedules of interferon. The methodological quality of the studies was high. However, all trials had been planned for a short-term evaluation based on bi…

AdultMalemedicine.medical_specialtyPhysiologymedicine.medical_treatmentHepacivirusGastroenterologyInterferonInternal medicinemedicineHumansClinical significanceProspective cohort studyHepatologybusiness.industryGastroenterologyInterferon-alphaInterferon-betaImmunotherapyMiddle AgedHepatologyHepatitis CConfidence intervalMeta-analysisAcute DiseaseImmunologyRNA ViralFemaleControlled Clinical Trials as TopicAcute hepatitis CViral diseasebusinessmedicine.drugDigestive Diseases and Sciences
researchProduct

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial

2009

A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these…

AdultMalemedicine.medical_specialtyRandomizationAdolescentPyridonesAdministration OralKaplan-Meier EstimateDeferoxamineInfusions SubcutaneousIron Chelating AgentsGastroenterologylaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansDeferiproneAdverse effectDecreased serum ferritinSurvival analysisbusiness.industryHematologySurgeryClinical trialDeferoxamineChelation thalassaemia clinical trials red blood cell disorders iron overload.Treatment OutcomechemistryFerritinsThalassemiaDrug Therapy CombinationFemalebusinessDeferiproneFollow-Up Studiesmedicine.drug
researchProduct

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria pati…

2002

Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (fiv…

AdultMalemedicine.medical_specialtyTime FactorsUrticariaUrinary systemImmunologyMethylhistamineProvocation testAdministration OralUrinePlaceboGastroenterologyBronchoconstrictor AgentsDrug HypersensitivityExcretionchemistry.chemical_compoundDouble-Blind MethodSodium BenzoateInternal medicineSodium GlutamatemedicineHumansSulfitesImmunology and AllergyCyclooxygenase InhibitorsTartrazineLeukotriene E4CreatinineAspirinDose-Response Relationship DrugAngioedemabusiness.industryMethylhistaminesMiddle AgedEndocrinologyItalychemistryChronic DiseaseFemaleFood AdditivesControlled Clinical Trials as Topicmedicine.symptombusinessBiomarkersAllergy
researchProduct

Effectiveness and safety of once-daily aminoglycosides: A meta-analysis

1996

The effectiveness and safety of once-daily versus several-times-daily aminoglycosides were studied in a meta-analysis. MEDLINE for 1988 to 1995 was searched, and additional studies were identified from review articles and references in retrieved articles. Studies selected for meta-analysis were randomized controlled clinical trials in nonneutropenic adult patients comparing the clinical effectiveness or nephrotoxicity or ototoxicity of once-daily with several-times-daily aminoglycosides. Differences between groups were expressed as odds ratios. The results were combined by the procedure of Mantel and Haenszel, and 95% confidence intervals and exact confidence intervals were computed. An odd…

Adultmedicine.medical_specialtyMEDLINEInfectionsDrug Administration ScheduleNephrotoxicityOtotoxicityInternal medicinemedicineHumansNetilmicinEar DiseasesAmikacinAgedAntibacterial agentPharmacologybusiness.industryHealth PolicyOdds ratioMiddle Agedmedicine.diseaseConfidence intervalAnti-Bacterial AgentsSurgeryClinical trialMeta-analysisKidney DiseasesControlled Clinical Trials as TopicGentamicinsbusinessAmerican Journal of Health-System Pharmacy
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct